Cutting-edge technology in the service of personalized care

IASO Group is ushering in a new era in diagnostic imaging through the installation of the most advanced hybrid positron emission tomography system, the Discovery MI Gen2 PET/CT system by GE HealthCare. This investment reflects the vision of IASO General Clinic to lead developments in Precision Medicine and personalized care, offering patients a top-tier diagnostic experience.

Discovery MI Gen2 is one of the most sophisticated diagnostic systems on a global basis, designed to offer high-resolution imaging, maximum safety, and an improved patient experience, combining state-of-the-art technologies such as:

• 2^nd generation digital detectors with SiPM and Time of Flight (ToF) technology;
• Q.Clear image reconstruction algorithm for accurate disease quantitation, image noise elimination, and simultaneous reduction of patient radiation dose to extremely low levels;
• The fully digital respiratory motion management system Motion Free;
• The automated patient positioning system Auto IN, to improve overall patient experience, increase safety, and ensure accurate results.  

The new PET/CT system, in the modern era of Theranostics, sets a new standard for the accurate diagnosis of oncological, neurological, and cardiological conditions, using specialized radiopharmaceuticals that enable:

• Oncology: Detection, diagnosis, initial staging, restaging, and evaluation of patients’ response to treatment in various neoplasms using radiopharmaceuticals such as FDG and PSMA (specialized medicine for prostate cancer).
• Cardiology: Study of myocardial perfusion and function with a new radiopharmaceutical available at the beginning of the new year: 18F -Flurpiridaz.
• Neurology: Diagnosis of Alzheimer’s disease, ¹⁸F-Vizamyl

Benefits for patients:

• Higher diagnostic accuracy and detection of smaller lesions
• Up to 40% r educed radiation exposure
• Rapid examination process and increased comfort
• Shorter examination duration
• Enhanced comfort and safety via the Auto-IN system
• Access to specialized radiopharmaceuticals for personalized diagnosis of oncological, cardiological, and neurological conditions

Benefits for healthcare professionals:

• 2^nd generation SiPM digital technology for top-tier sensitivity
• Enhanced diagnostic precision via ToF Technology
• Q.Clear algorithm for quantitative accuracy and noise-free imaging
• Motion Free system for scans without respiratory distortion
• Ability to utilize specialized radiopharmaceuticals for advanced analysis.

The system is operated by specialized medical and paramedical personnel with multiannual experience in Nuclear Medicine, top-level scientific training, and who are renowned in the field, ensuring the provision of high-quality services, with a focus on scientific accuracy, technological excellence, and the human-centered approach every patient deserves, creating an environment of safety, trust, and meaningful care.

With the acquisition of Discovery MI Gen2 and the utilization of new radiopharmaceuticals, IASO Group reinforces its role as a leading healthcare center in Greece, introducing cutting-edge technologies that supplement preventive medicine, diagnostic reliability, and therapeutic monitoring.

From left to right, Ms. Christina Konstantinou, Nurse, IASO General Clinic; Mr. Vasileios Prasopoulos, Nuclear Medicine Physician, Director, PET/CT Department, IASO General Clinic; Mr. Giannis Kagklis, Radiation Physicist, Medical Physicist, IASO General Clinic; Ms. Eleni Koumpou, Technologist, PET C/T Department, IASO General Clinic; Ms. Niki Chatzaki, Secretary, Nuclear Medicine - PET C/T Department, IASO General Clinic.

For additional journalistic information: Nancy Christopoulou, Marketing, Communication & CSR Director, Commercial & Marketing Department, IASO Group, Tel: 210 6383917, E-mail: [email protected]